# PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

> **NCT05233436** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 21 (actual)

## Conditions studied

- Advanced Solid Tumors
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Urothelial Cancer
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinomas

## Interventions

- **DRUG:** PF-07265028
- **BIOLOGICAL:** Sasanlimab

## Key facts

- **NCT ID:** NCT05233436
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-24
- **Primary completion:** 2023-10-16
- **Final completion:** 2023-10-16
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study terminated based on internal business considerations and was not based on safety reasons
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233436, "PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05233436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*